Charles Mondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Charles Mondo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed ElSayed
Alzaiem Alazhari University
1 shared publication - Albertino Damasceno
Faculty of Medicine, Eduardo Mondlane University , Maputo
1 shared publication - Alex Grinvalds
Population Health Research Institute, McMaster University, Hamilton, CA
1 shared publication - Hisham Dokainish
Population Health Research Institute, McMaster University, Hamilton, CA
1 shared publication - Kamilu Musa Karaye
Department of Medicine, Bayero University and Aminu Kano Teaching Hospital, Kano, Nigeria
1 shared publication - Karen Sliwa
Cape Heart Institute, Faculty of Health Sciences, University of Cape Town , Cape Town
1 shared publication
Latest Publications
- Open Access
- 4 January 2021
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 16 (1)
Clinical Profiles and Outcomes of Heart Failure in Five African Countries: Results from INTER-CHF Study
A wide knowledge gap exists on the clinical profiles and outcomes of heart failure (HF) in sub-Saharan Africa. To determine the clinical profiles and outcomes of HF patients from five African countries. The INTERnational Congestive Heart Failure Study (INTER-CHF) is a prospective, multicenter cohort study. A total of 1,294 HF patients were consecutively recruited from Nigeria (383 patients), South Africa (169 patients), Sudan (501 patients), Uganda (151patients), and Mozambique (90 patients). HF was defined according to the Boston criteria for diagnosis. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) score. Of the 1294 patients, 51.4% were recruited as out-patients, 53.7% had HF with reduced ejection fraction (EF), 30.1% had HF with mid-range EF and 16.2% had HF with preserved EF (16.2%). The commonest etiologies of HF were hypertensive heart disease (35%) and ischemic heart disease (20%). The mean MoCA score was highest in Uganda (24.3 ± 1.1) and lowest in Sudan (13.6 ± 0.3). Prescriptions for guideline-recommended HF therapies were poor; only 1.2% of South African patients received an Implantable Cardioverter Defibrillator, and none of the patients received Cardiac Resynchronised Therapy. The composite outcome of death or HF hospitalization at one year among the patients was highest in Sudan (59.7%) and lowest in Mozambique (21.1%). Six variables were associated with higher mortality risk, while digoxin use (adjusted hazard ratio [aHR]: 0.69; 95% confidence interval [CI]: 0.49–0.97; p = 0.034) and 10mmHg unit increase in systolic blood pressure (aHR 0.86; 95%CI 0.81–0.93; p < 0.001) were associated with lower risk for mortality. This is the largest HF study in Africa that included in- and out-patients from the West, East, North, Central and South African sub-regions. Clinically relevant differences, including cognitive functional impairment, were found between the involved countries.
- 4 January 2021
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 16 (1)
Open AccessClinical Profiles and Outcomes of Heart Failure in Five African Countries: Results from INTER-CHF Study
A wide knowledge gap exists on the clinical profiles and outcomes of heart failure (HF) in sub-Saharan Africa. To determine the clinical profiles and outcomes of HF patients from five African countries. The INTERnational Congestive Heart Failure Study (INTER-CHF) is a prospective, multicenter cohort study. A total of 1,294 HF patients were consecutively recruited from Nigeria (383 patients), South Africa (169 patients), Sudan (501 patients), Uganda (151patients), and Mozambique (90 patients). HF was defined according to the Boston criteria for diagnosis. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) score. Of the 1294 patients, 51.4% were recruited as out-patients, 53.7% had HF with reduced ejection fraction (EF), 30.1% had HF with mid-range EF and 16.2% had HF with preserved EF (16.2%). The commonest etiologies of HF were hypertensive heart disease (35%) and ischemic heart disease (20%). The mean MoCA score was highest in Uganda (24.3 ± 1.1) and lowest in Sudan (13.6 ± 0.3). Prescriptions for guideline-recommended HF therapies were poor; only 1.2% of South African patients received an Implantable Cardioverter Defibrillator, and none of the patients received Cardiac Resynchronised Therapy. The composite outcome of death or HF hospitalization at one year among the patients was highest in Sudan (59.7%) and lowest in Mozambique (21.1%). Six variables were associated with higher mortality risk, while digoxin use (adjusted hazard ratio [aHR]: 0.69; 95% confidence interval [CI]: 0.49–0.97; p = 0.034) and 10mmHg unit increase in systolic blood pressure (aHR 0.86; 95%CI 0.81–0.93; p < 0.001) were associated with lower risk for mortality. This is the largest HF study in Africa that included in- and out-patients from the West, East, North, Central and South African sub-regions. Clinically relevant differences, including cognitive functional impairment, were found between the involved countries.
- 16 October 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (11) , 1029-1034
ANTI‐OXIDANT EFFECTS OF ATORVASTATIN IN DEXAMETHASONE‐INDUCED HYPERTENSION IN THE RAT
SUMMARY: Dexamethasone (Dex)‐induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide () production. Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced production in various forms of hypertension. In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in in Sprague‐Dawley (SD) rats, thereby reducing blood pressure. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days. Dexamethasone (10 µg/kg per day, s.c.) or saline was started after 4 days in Ato‐treated and non‐treated rats and continued for 11–13 days. Systolic blood pressure (SBP) was measured on alternate days using the tail‐cuff method. Endothelial function was assessed by acetylcholine‐induced vasorelaxation and phenylephrine‐induced vasoconstriction in aortic segments. Vascular eNOS mRNA was assessed by semi‐quantitative reverse transcription–polymerase chain reaction. In rats treated with Dex alone, SBP was increased from 109 ± 2 to 133 ± 2 mmHg on Days 4 and Day 14, respectively (P < 0.001). In the Ato + Dex group, SBP was increased from 113 ± 2 to 119 ± 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05). Endothelial‐dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively). Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001). Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex‐treated SD rats.
- 16 October 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (11) , 1029-1034
ANTI‐OXIDANT EFFECTS OF ATORVASTATIN IN DEXAMETHASONE‐INDUCED HYPERTENSION IN THE RAT
SUMMARY: Dexamethasone (Dex)‐induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide () production. Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced production in various forms of hypertension. In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in in Sprague‐Dawley (SD) rats, thereby reducing blood pressure. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days. Dexamethasone (10 µg/kg per day, s.c.) or saline was started after 4 days in Ato‐treated and non‐treated rats and continued for 11–13 days. Systolic blood pressure (SBP) was measured on alternate days using the tail‐cuff method. Endothelial function was assessed by acetylcholine‐induced vasorelaxation and phenylephrine‐induced vasoconstriction in aortic segments. Vascular eNOS mRNA was assessed by semi‐quantitative reverse transcription–polymerase chain reaction. In rats treated with Dex alone, SBP was increased from 109 ± 2 to 133 ± 2 mmHg on Days 4 and Day 14, respectively (P < 0.001). In the Ato + Dex group, SBP was increased from 113 ± 2 to 119 ± 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05). Endothelial‐dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively). Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001). Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex‐treated SD rats.